MA51893A - Ligands de gm-csf ou du récepteur gm-csf destinés à être utilisés dans le traitement d'une malignité hématologique chez un patient ayant subi un allo-hct - Google Patents

Ligands de gm-csf ou du récepteur gm-csf destinés à être utilisés dans le traitement d'une malignité hématologique chez un patient ayant subi un allo-hct

Info

Publication number
MA51893A
MA51893A MA051893A MA51893A MA51893A MA 51893 A MA51893 A MA 51893A MA 051893 A MA051893 A MA 051893A MA 51893 A MA51893 A MA 51893A MA 51893 A MA51893 A MA 51893A
Authority
MA
Morocco
Prior art keywords
csf
malignity
allo
hct
hematological
Prior art date
Application number
MA051893A
Other languages
English (en)
French (fr)
Inventor
Burkhard Becher
Sonia Tugues
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18194549.4A external-priority patent/EP3623382A1/en
Application filed by Univ Zuerich filed Critical Univ Zuerich
Publication of MA51893A publication Critical patent/MA51893A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA051893A 2018-02-22 2019-02-22 Ligands de gm-csf ou du récepteur gm-csf destinés à être utilisés dans le traitement d'une malignité hématologique chez un patient ayant subi un allo-hct MA51893A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18158169 2018-02-22
EP18189562 2018-08-17
EP18194549.4A EP3623382A1 (en) 2018-09-14 2018-09-14 Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US16/269,572 US11655293B2 (en) 2018-02-22 2019-02-07 Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT

Publications (1)

Publication Number Publication Date
MA51893A true MA51893A (fr) 2020-12-30

Family

ID=67616687

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051893A MA51893A (fr) 2018-02-22 2019-02-22 Ligands de gm-csf ou du récepteur gm-csf destinés à être utilisés dans le traitement d'une malignité hématologique chez un patient ayant subi un allo-hct

Country Status (11)

Country Link
US (3) US11655293B2 (cg-RX-API-DMAC7.html)
EP (1) EP3755715A1 (cg-RX-API-DMAC7.html)
JP (1) JP7278296B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200123434A (cg-RX-API-DMAC7.html)
CN (1) CN111886248B (cg-RX-API-DMAC7.html)
AU (1) AU2019224550A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020017253A2 (cg-RX-API-DMAC7.html)
CA (1) CA3091536A1 (cg-RX-API-DMAC7.html)
MA (1) MA51893A (cg-RX-API-DMAC7.html)
MX (2) MX2020008792A (cg-RX-API-DMAC7.html)
WO (1) WO2019162472A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
MX2022011111A (es) * 2020-03-08 2023-03-02 Humanigen Inc Métodos para tratar infección de coronavirus y lesión pulmonar inducida por inflamación resultante.
TW202317637A (zh) * 2021-08-26 2023-05-01 日商協和麒麟股份有限公司 與cd116及cd131結合之雙特異性抗體

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0009772A (pt) 1999-04-14 2002-01-08 Us Health Composições contendo imunotoxinas e agentes que inibem a maturação de células dendrìticas para induzir tolerância imune a um enxerto
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
ES2918209T3 (es) 2005-05-18 2022-07-14 Morphosys Ag Anticuerpos anti-GM-CSF y usos a partir de los mismos
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトgm−csfに結合するヒトのモノクローナル抗体並びにその抗原結合部分
KR101395515B1 (ko) * 2006-02-08 2014-05-14 모르포테크, 인크. 항원성 gm-csf 펩티드 및 gm-csf에 대한 항체
KR101481844B1 (ko) 2006-03-27 2015-01-13 메디뮨 리미티드 Gm-csf 수용체에 대한 결합 성분
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US8679502B2 (en) 2007-11-13 2014-03-25 Evec Inc. Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same
CA2717987C (en) 2008-04-29 2018-11-13 Micromet Ag Inhibitors of gm-csf and il-17 for therapy
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
EP3514169B1 (en) 2010-11-26 2024-03-06 Molecular Partners AG Designed repeat proteins binding to serum albumin
BR112013033944A2 (pt) * 2011-07-06 2017-12-19 Morphosys Ag combinação sinérgica
SG11201408196RA (en) 2012-06-28 2015-03-30 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
CN104995210A (zh) 2012-09-20 2015-10-21 莫弗系统股份公司 类风湿关节炎的治疗
US9658228B2 (en) * 2013-01-30 2017-05-23 The Board of Trustees of the Leland University Junior University Method to detect the onset and to monitor the recurrence of chronic graft versus host disease in transplantation patients
JP6490419B2 (ja) 2014-12-24 2019-03-27 学校法人関西医科大学 制御性t細胞分化誘導剤
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT

Also Published As

Publication number Publication date
US20190256587A1 (en) 2019-08-22
US20210070851A1 (en) 2021-03-11
AU2019224550A1 (en) 2020-09-17
MX2020008792A (es) 2020-10-14
US12384839B2 (en) 2025-08-12
RU2020129401A (ru) 2022-03-22
KR20200123434A (ko) 2020-10-29
EP3755715A1 (en) 2020-12-30
US20230340100A1 (en) 2023-10-26
JP7278296B2 (ja) 2023-05-19
CN111886248A (zh) 2020-11-03
US11655293B2 (en) 2023-05-23
MX2023001357A (es) 2023-02-27
BR112020017253A2 (pt) 2020-12-22
CN111886248B (zh) 2025-03-04
JP2021514368A (ja) 2021-06-10
RU2020129401A3 (cg-RX-API-DMAC7.html) 2022-03-22
CA3091536A1 (en) 2019-08-29
WO2019162472A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
EP3755805A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF NON-AGE-RELATED HEARING DAMAGE IN AN INDIVIDUAL
EP3873335A4 (en) CHARACTERIZATION OF THERAPEUTIC EFFECTIVENESS OF NEUROSTIMULATION
EP3802798A4 (en) CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T) FOR TREATMENT OF CANCER
EP3455205A4 (en) PEPTIDOMIMETICS FOR TREATING A NOVOVIRUS INFECTION
EP3641829A4 (en) INTERFERON PRODRUG FOR TREATMENT OF CANCER
EP3393475C0 (en) CIFORADENT ALONE OR IN COMBINATION WITH ATEZOLIZUMAB FOR USE IN THE TREATMENT OF CANCER
EP3616097A4 (en) Dose reduction for medical imaging using deep convolutional neural networks
EP3600281A4 (en) COMBINATION THERAPY FOR TREATING OR PREVENTING TUMORS
MA49131A (fr) Utilisation d'antagonistes de klk5 pour le traitement d'une maladie
MA50155A (fr) Acides aminés à chaîne ramifiée pour le traitement d'une lésion neuronale
EP3552611A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER WITH CRYSTALLINE TETRAARSEN HEXOXIDE POLYMORPH
EP3814286A4 (en) Continuous flow wastewater treatment system
EP3778592A4 (en) RADIOPHARMIC AGAINST PSMA FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
EP3589307A4 (en) REGENERATIVE FUNCTIONAL NEURONES TO TREAT NEURONAL INJURIES CAUSED BY CIRCUIT DISORDER
EP3645044A4 (en) USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, ELEMENT A5 ANTIBODIES TO TREAT GLAUCOMA
EP3498362A4 (en) DISK-LIKE FILTER MODULE FOR WATER TREATMENT AND FILTER ARRANGEMENT FOR WATER TREATMENT THEREFOR
EP3861131A4 (en) GENE THERAPY FOR THE TREATMENT OF PROPIONIC ACIDosis
EP3846821A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF LIVER DISEASES
EP3403675A4 (en) ADENO-ASSOCIATED VIRUSVIRION FOR USE IN THE TREATMENT OF EPILEPSIA
EP3432892A4 (en) USEFUL MANNOSE-DERIVED ANTAGONISTS FROM FIMH FOR THE TREATMENT OF DISEASES
EP3504204A4 (en) INDAZOLYL-L, 2,4-THIADIAZOLAMINE AND RELATED COMPOUNDS FOR INHIBITING RHO-ASSOCIATED PROTEIN KINASES AND FOR TREATING DISEASES
EP4069700A4 (en) MACROCYCLES FOR USE IN TREATMENT OF DISEASES
MA55490A (fr) Mutéine de lipocaline pour le traitement de l'asthme
MA43861A (fr) Inhibiteurs il-8 destinés à être utilisés dans le traitement d'une neuropathie périphérique induite par une chimiothérapie
EP3730144A4 (en) AGENTS FOR TREATMENT OF DISEASES OF THE NERVOUS SYSTEM